BRIVANIB (B) IN ADVANCED OVARIAN CANCER (OC): SUBSET RESULTS OF A PHASE 2 RANDOMIZED DISCONTINUATION TRIAL (RDT)

被引：0
|
作者：
Kaye, S. B. [1 ,2 ]
Siu, L. L. [3 ]
Jassem, J. [4 ]
Medioni, J. [5 ]
Soetekouw, P. M. M. B. [6 ]
Slater, S. [7 ]
Rudin, C. M. [8 ]
Schwartz, G. K. [9 ]
De Jonge, M. [10 ]
O'Dwyer, P. [11 ]
Baudelet, C. [12 ]
Chen, A. [13 ]
Ratain, M. J. [14 ]
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Inst Canc Res, Sutton, Surrey, England
[3] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada
[4] Med Univ Gdansk, Gdansk, Poland
[5] Hop Europeen Georges Pompidou, Dept Med Oncol, Paris, France
[6] Maastricht Univ, Med Ctr, Div Med Oncol, Maastricht, Netherlands
[7] Beatson W Scotland Canc Ctr, Dept Med Oncol, Glasgow, Lanark, Scotland
[8] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[9] Mem Sloan Kettering Canc Ctr, Melanoma & Sarcoma Serv, New York, NY 10021 USA
[10] Erasmus Univ, Med Ctr, Dept Med Oncol, Rotterdam, Netherlands
[11] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[12] Brstol Myers Squibb, Res & Dev, Braine Lalleud, Belgium
[13] Bristol Myers Squibb Co, Res & Dev, Wallingford, CT 06492 USA
[14] Univ Chicago, Dept Med, Chicago, IL 60637 USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：319 / 319
页数：1
相关论文
共 50 条
  • [1] Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT).
    Ratain, M. J.
    Schwartz, G. K.
    Oza, A. M.
    Rudin, C. M.
    Kaye, S. B.
    De Jonge, M. J.
    Khayat, D.
    Awada, A.
    Sawyer, M. B.
    Obel, J. C.
    Medioni, J.
    Evans, T. R. J.
    De Greve, J.
    Soetekouw, P. M.
    Baurain, J.
    O'Dwyer, P. J.
    Hartman, C.
    Poulart, V.
    Walters, I. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT).
    Buckanovich, R. J.
    Berger, R.
    Sella, A.
    Sikic, B. I.
    Shen, X.
    Ramies, D. A.
    Smith, D. C.
    Vergote, I. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.
    Schwartz, G. K.
    Maki, R. G.
    Ratain, M. J.
    Undevia, S. D.
    Jones, R. L.
    Rudin, C. M.
    Siu, L. L.
    Brockstein, B.
    Khayat, D.
    Gil, T.
    De Jonge, M. J.
    Sawyer, M. B.
    Evans, T. R. J.
    Medioni, J.
    O'Dwyer, P. J.
    Hartman, C.
    Poulart, V.
    Walters, I. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Phase 2 randomized discontinuation trial (RDT) of XL184 in patients (pts) with advanced solid tumors
    Schoeffski, P.
    Sgroi, M.
    Burris, H. A.
    Lutzky, J.
    Rearden, T.
    Sikic, B.
    Stephenson, J., Jr.
    Elhardt, D.
    Lee, Y.
    Kurzrock, R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 117 - 117
  • [5] Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
    Smith, David C.
    Smith, Matthew R.
    Sweeney, Christopher
    Elfiky, Aymen A.
    Logothetis, Christopher
    Corn, Paul G.
    Vogelzang, Nicholas J.
    Small, Eric J.
    Harzstark, Andrea L.
    Gordon, Michael S.
    Vaishampayan, Ulka N.
    Haas, Naomi B.
    Spira, Alexander I.
    Lara, Primo N., Jr.
    Lin, Chia-Chi
    Srinivas, Sandy
    Sella, Avishay
    Schoeffski, Patrick
    Scheffold, Christian
    Weitzman, Aaron L.
    Hussain, Maha
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04) : 412 - 419
  • [6] Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
    Jones, Robin L.
    Ratain, Mark J.
    O'Dwyer, Peter J.
    Siu, Lillian L.
    Jassem, Jacek
    Medioni, Jacques
    DeJonge, Maja
    Rudin, Charles
    Sawyer, Michael
    Khayat, David
    Awada, Ahmad
    de Vos-Geelen, Judith M. P. G. M.
    Evans, T. R. Jeffry
    Obel, Jennifer
    Brockstein, Bruce
    DeGreve, Jacques
    Baurain, Jean-Francois
    Maki, Robert
    D'Adamo, David
    Dickson, Mark
    Undevia, Samir
    Geary, David
    Janisch, Linda
    Bedard, Philippe L.
    Razak, Albiruni R. Abdul
    Kristeleit, Rebecca
    Vitfell-Rasmussen, Joanna
    Walters, Ian
    Kaye, Stan B.
    Schwartz, Gary
    EUROPEAN JOURNAL OF CANCER, 2019, 120 : 132 - 139
  • [7] Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT)
    Winer, Eric P.
    Tolaney, Sara
    Nechushtan, Hovav
    Berger, Raanan
    Kurzrock, Razelle
    Ron, Ilan-Gil
    Schoffski, Patrick
    Awada, Ahmad
    Yasenchak, Christopher A.
    Burris, Howard A.
    Ramies, David A.
    Rafferty, Teresa
    Shen, Xiaodong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT)
    Daud, Adil
    Kluger, Harriet M.
    Edelman, Gerald
    Gordon, Michael S.
    Schimmoller, Frauke
    Weitzman, Aaron
    Samuel, Thomas A.
    Moussa, Ali H.
    Flaherty, Keith
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] PHASE 2 RANDOMIZED DISCONTINUATION TRIAL (RDT) OF TIVOZANIB IN PATIENTS WITH RENAL CELL CARCINOMA (RCC): RESULTS IN PATIENTS RANDOMIZED TO TIVOZANIB VS. PLACEBO
    Nosov, D. A.
    Bhargava, P.
    Esteves, B.
    Al-Adhami, M.
    Lipatov, O.
    Lyulko, A. A.
    Anischenko, A. A.
    Chacko, R.
    Doval, D. C.
    Slichenmyer, W.
    ANNALS OF ONCOLOGY, 2010, 21 : 271 - 271
  • [10] Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).
    Hellerstedt, Beth A.
    Edelman, Gerald
    Vogelzang, Nicholas J.
    Kluger, Harriet M.
    Yasenchak, Christopher A.
    Shen, Xiaodong
    Ramies, David A.
    Gordon, Michael S.
    Lara, Primo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345